Long-term tetrahydroaminoacridine treatment and quantitative EEG in Alzheimer's disease

E. A. Kogan, R. G. Verchovsky, M. Y. Neufeld, S. Sh Klimovitsky, T. A. Treves, A. D. Korczyn

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


The development of therapies for Alzheimer's disease (AD) has focused on drags designed to correct the loss of cholinergic function within the central nervous system. Quantitative EEG (qEEG) changes associated with AD consist of background slowing. One way to study the effects of cholinergic drags may be through assessment of their qEEG effects. The aim of the current work was to evaluate the effect of long-term treatment with tetrahydroaminoacridine (THA) on qEEG in AD patients.

Original languageEnglish
Title of host publicationNeuropsychiatric Disorders An Integrative Approach
PublisherSpringer Wien
Number of pages4
ISBN (Print)9783211735732
StatePublished - 2007

Publication series

NameJournal of Neural Transmission, Supplementa
ISSN (Print)0303-6995


  • Alzheimer's disease
  • Dementia
  • cholinesterase inhibitors
  • qEEG
  • tetrahydroaminoacridine
  • therapy


Dive into the research topics of 'Long-term tetrahydroaminoacridine treatment and quantitative EEG in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this